Display options
Cite
Prabhakaran S, Liebeskind DS, Cotsonis G, et al. Lipid Levels and Short-Term Risk of Recurrent Brain Infarcts in Symptomatic Intracranial Stenosis. J Stroke Cerebrovasc Dis. 2021;31(1):106141doi: 10.1016/j.jstrokecerebrovasdis.2021.106141.
Prabhakaran, S., Liebeskind, D. S., Cotsonis, G., Nizam, A., Feldmann, E., Sangha, R. S., Campo-Bustillo, I., Romano, J. G. (2021). Lipid Levels and Short-Term Risk of Recurrent Brain Infarcts in Symptomatic Intracranial Stenosis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 31(1), 106141. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106141
Prabhakaran, Shyam, et al. "Lipid Levels and Short-Term Risk of Recurrent Brain Infarcts in Symptomatic Intracranial Stenosis." Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association vol. 31,1 (2021): 106141. doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106141
Prabhakaran S, Liebeskind DS, Cotsonis G, Nizam A, Feldmann E, Sangha RS, Campo-Bustillo I, Romano JG. Lipid Levels and Short-Term Risk of Recurrent Brain Infarcts in Symptomatic Intracranial Stenosis. J Stroke Cerebrovasc Dis. 2021 Oct 25;31(1):106141. doi: 10.1016/j.jstrokecerebrovasdis.2021.106141. Epub 2021 Oct 25. PMID: 34710776.
Copy Download .nbib Format: NLM
Share it on

J Stroke Cerebrovasc Dis. 2021 Oct 25;31(1):106141. doi: 10.1016/j.jstrokecerebrovasdis.2021.106141. Epub 2021 Oct 25.

Lipid Levels and Short-Term Risk of Recurrent Brain Infarcts in Symptomatic Intracranial Stenosis.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Shyam Prabhakaran, David S Liebeskind, George Cotsonis, Azhar Nizam, Edward Feldmann, Rajbeer S Sangha, Iszet Campo-Bustillo, Jose G Romano,

Affiliations

  1. The University of Chicago, Chicago, IL, USA. Electronic address: [email protected].
  2. University of California at Los Angeles, Los Angeles, CA, USA.
  3. Emory University, Atlanta, GA, USA.
  4. The University of Massachusetts Medical School-Baystate, Springfield, MA, USA.
  5. University of Alabama at Birmingham, Birmingham, AL, USA.
  6. University of Miami, Miami, FL, USA.

PMID: 34710776 DOI: 10.1016/j.jstrokecerebrovasdis.2021.106141

Abstract

OBJECTIVES: Hyperlipidemia is a strong risk factor for intracranial atherosclerotic disease (ICAD) and clinical stroke recurrence. We explored the effect of serum lipid levels on subclinical infarct recurrence in the Mechanisms of earlY Recurrence in Intracranial Atherosclerotic Disease (MYRIAD) study.

MATERIALS AND METHODS: We included enrolled MYRIAD patients with lipid measurements and brain MRI at baseline and brain MRI at 6-8 weeks. Infarct recurrence was defined as new infarcts in the territory of the symptomatic artery on brain MRI at 6-8 weeks compared to baseline brain MRI. We assessed the association between baseline total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels and recurrent infarct at 6-8 weeks using multivariable logistic regression.

RESULTS: Among 74 patients (mean age 64.2±12.9 years, 59.5% were white, 60.8% men), 20 (27.0%) had new or recurrent infarcts. Mean HDL-C (37.2 vs. 43.9 mg/dL, P=0.037) was lower and TG (113.5 vs. 91.3 mg/dL, P=0.008) was higher while TC (199.8 vs. 174.3 mg/dL, P=0.061) and LDL-C (124.3 vs. 101.2 mg/dL, P=0.053) were nominally higher among those with recurrent infarcts than those without. LDL-C (adj. OR 1.022, 95% CI 1.004-1.040, P=0.015) and TG (adj. OR 1.009, 95% CI 1.001-1.016, P=0.021) were predictors of recurrent infarct at 6-8 weeks adjusting for other clinical and imaging factors.

CONCLUSIONS: Baseline cholesterol markers can predict early infarct recurrence in patients with symptomatic ICAD. More intensive and rapid lipid lowering drugs may be required to reduce risk of early recurrence.

Copyright © 2021 Elsevier Inc. All rights reserved.

Keywords: Cholesterol; Magnetic resonance imaging; Statin; Stroke

Conflict of interest statement

Declaration of Competing Interest Dr. Prabhakaran reports grants from NIH during the conduct of the study; grants from AHRQ, personal fees from Abbvie, and personal fees from UpToDate outside the subm

Publication Types

Grant support